An in silico approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

• DOI: 10.1016/j.heliyon.2024.e25837
• Publication Date: 2024-02-09T06:39:32Z
• Authors: Suvro Biswas; Mohasana Akter Mita; Shamima Afrose; Md. Robiul Hasan; Mst. Sharmin Sult...; Shahriar Zaman; Md. Abu Saleh
• Keywords: 2019-20 coronavirus outbreak; Coronavirus Infections; Betacoronavirus; Coronavirus; Pandemic

A deadly respiratory disease Middle East Respiratory Syndrome (MERS) is caused by a perilous virus known as MERS-CoV, which has severe impact on human health. Currently, there no approved vaccine, prophylaxis, or antiviral therapeutics for preventing MERS-CoV infection. Due to its inexorable and integral role in the maturation replication of virus, 3C-like protease unavoidly viable therapeutic target. In this study, 2369 phytoconstituents were enlisted from Japanese medicinal plants, these compounds screened against identify feasible inhibitors. The best three identified Kihadanin B, Robustaflavone, 3-beta-O- (